Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2015-05-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/jc.2015-1259PMID 25955225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis.

  2014cited by this paper
• Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.

  2014cited by this paper
• Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis

  2013cited by this paper
• Severe hypocalcemia following denosumab injection in a hemodialysis patient.

  2012cited by this paper
• Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients

  2012cited by this paper
• Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

  2010cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland--study in rats.

  2008cited by this paper
• Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis.

  2007cited by this paper
• Direct injection of calcitriol or its analog into hyperplastic parathyroid glands induces apoptosis of parathyroid cells.

  2006cited by this paper
• Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.

  2005cited by this paper
• Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.

  2005cited by this paper
• The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

  2005cited by this paper
• K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

  2003cited by this paper
• PTH Differentially Regulates Expression of RANKL and OPG

  2003cited by this paper
• Parathyroid Hormone Stimulates Receptor Activator of NFκB Ligand and Inhibits Osteoprotegerin Expression via Protein Kinase A Activation of cAMP-response Element-binding Protein*

  2002cited by this paper
• Osteoprotegerin Inhibits Artery Calcification Induced by Warfarin and by Vitamin D

  2001cited by this paper
• Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis*

  2001cited by this paper
• Increased risk of hip fracture among patients with end-stage renal disease.

  2000cited by this paper
• Risk factors for hip fracture among patients with end-stage renal disease.

  2000cited by this paper
• Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

  2000cited by this paper
• Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism.

  2000cited by this paper
• Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy.

  2000cited by this paper
• Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism.

  1997cited by this paper
• Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism.

  1996cited by this paper
• Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.

  1995cited by this paper
• Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis.

  1990cited by this paper

• Severe hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent

  2025cites this paper
• Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

  2025cites this paper
• The Conundrum of Medical Fracture Prevention in Chronic Kidney Disease—Summary of the Evidence and Pragmatic Clinical Guidance

  2025cites this paper
• Circulating Angiopoietin-like proteins in Strongyloides Stercoralis infection and reversal following treatment

  2025cites this paper
• Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab

  2025cites this paper
• Clinical approaches to osteoporosis in patients with chronic kidney disease: A comprehensive review

  2025influential citation
• Advancing care: optimizing osteoporosis treatment in the older and oldest old population

  2025cites this paper
• Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting

  2024influential citation
• Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease

  2024cites this paper
• The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease

  2024cites this paper
• Incidence and predictors of hypocalcemia in end-stage renal disease patients on denosumab therapy: A systematic review and meta-analysis

  2024cites this paper
• Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.

  2024cites this paper
• Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative

  2023cites this paper
• Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism

  2023influential citation
• Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review

  2023cites this paper
• Bones of contention: Predicting and preventing fractures in patients receiving peritoneal dialysis

  2023influential citation
• Severe Refractory Hypocalcemia Caused by Denosumab

  2023cites this paper
• Effects of denosumab on bone mineral density and bone metabolism in patients with end‐stage renal disease: A systematic review and meta‐analysis

  2023cites this paper
• Effect of hemodialysis combined with calcitriol on cardiac function and BNP in patients with hyperparathyroidism secondary to nephropathy.

  2023cites this paper
• Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials

  2022cites this paper
• Management of fracture risk in CKD—traditional and novel approaches

  2022cites this paper
• Management of osteoporosis in patients with chronic kidney disease

  2022cites this paper
• Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment.

  2021cites this paper
• Serum nuclear factor IB as a novel and noninvasive indicator in the diagnosis of secondary hyperparathyroidism

  2021cites this paper
• Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety

  2021cites this paper
• Denosumab for dialysis patients with osteoporosis: A cohort study

  2020cites this paper
• Long Term Effect of Denosumab on Densitometry Evolution in Women Patients

  2020cites this paper
• Current and Emerging Treatment of Osteoporosis

  2020cites this paper
• Innovative rheumatologische und osteologische Medikation im Kontext der chronischen Niereninsuffizienz – Was ist möglich?

  2020cites this paper
• Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases

  2020cites this paper
• The relative influence of serum ionized calcium and 25-hydroxyvitamin D in regulating PTH secretion in healthy subjects.

  2019cites this paper
• Off-label uses of denosumab in metabolic bone diseases.

  2019cites this paper
• Denosumab Improves Glomerular Filtration Rate in Osteoporotic Patients With Normal Kidney Function by Lowering Serum Phosphorus

  2019cites this paper
• Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial

  2019influential citation
• Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis

  2019influential citation
• Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies

  2018cites this paper
• Mineral and bone disorders in conventional hemodialysis: Challenges and solutions

  2018cites this paper
• Denosumab‐Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease

  2017cites this paper
• Safety and efficacy of denosumab in osteoporotic hemodialysed patients

  2017cites this paper
• Alfacalcidol in CKD-MBDA Fresh Look

  2017cites this paper
• Denosumab for the treatment of osteoporosis

  2017cites this paper
• Vitamin D and Bone in Chronic Kidney Disease

  2016cites this paper
• Smjernice za prevenciju, praćenje i liječenje poremećaja koštano-mineralnog metabolizma u bolesnika s kroničnom bubrežnom bolesti [Guidelines for the prevention, monitoring and therapy of chronic kidneydisease-metabolic bone disease in patients with chronic kidney disease]

  2016cites this paper
• [Targeted therapy for mineral and bone disorder].

  2016cites this paper
• Combination Therapy of Denosumab and Calcitriol for a Renal Transplant Recipient with Severe Bone Loss due to Therapy-Resistant Hyperparathyroidism.

  2016cites this paper
• Denosumab in the treatment of hypercalcemia secondary to malignancy

  2015cites this paper
• Étude de la réparation osseuse dans un modèle de souris urémiques sauvages et invalidées pour le gène de l’Apolipoprotéine E

  2015cites this paper